Pharmaceuticals, Biotechnology and Life Sciences
CAMBRIDGE, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on…
RICHMOND, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) — BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic…
IRVINE, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet…
PHILADELPHIA, Sept. 25, 2024 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and…
CHASKA, Minn., Sept. 25, 2024 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and…
MDxHealth Announces Launch of Offering of Ordinary Shares IRVINE, CA, and HERSTAL, BELGIUM –September 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:…
Bio-Sourcing, a pioneering Belgian biotherapeutic company, has secured €2.5M in grants and €10M in equity from the European Innovation Council…
SLEEVER®, a French family-owned group International SME and innovative leader in shrinksleeve label technology, and CARBIOS, (Euronext Growth Paris : ALCRB), a pioneer in the…
InflaRx N.V., a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today said that Vilobelimab demonstrates significant improvement in reduction of draining tunnels, total lesion count, International Hidradenitis Suppurativa Score 4 and the newly introduced modified-HiSCR
LOS ANGELES, Sept. 24, 2024 (GLOBE NEWSWIRE) — Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces a…